Cargando…

Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines

Biological medicines are considered as a cornerstone in the therapy of rheumatoid arthritis (RA). They change the course of the disease and improve the quality of life of patients. To this date there has been no study comparing the quality of life of and cost of RA therapy in Bulgaria. This fact is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boyadzieva, Vladimira V., Stoilov, Nikolay, Stoilov, Rumen M., Tachkov, Konstantin, Kamusheva, Maria, Mitov, Konstantin, Petrova, Guenka I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058036/ https://www.ncbi.nlm.nih.gov/pubmed/30072903 http://dx.doi.org/10.3389/fphar.2018.00794

Ejemplares similares

Real World Experience of Disease Activity in Patients With Rheumatoid Arthritis and Response to Treatment With Varios Biologic DMARDs
por: Boyadzhieva, Vladimira, et al.
Publicado: (2018)

How Managed Entry Agreements Influence the Patients’ Affordability to Biological Medicines—Bulgarian Example
por: Mitkova, Zornitsa, et al.
Publicado: (2023)

Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2021)

Pilot Study on the Cost of Some Oncohematology Diseases in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2019)

Pharmacotherapeutic Patterns and Patients’ Access to Pharmacotherapy for Some Rare Diseases in Bulgaria – A Pilot Comparative Study
por: Kamusheva, Maria, et al.
Publicado: (2021)

Economic consequences of the vaccination against hepatitis A in the Bulgarian healthcare setting
por: Dimitrova, Maria, et al.
Publicado: (2014)

Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis
por: Manova, Manoela, et al.
Publicado: (2018)

Therapeutic Results and Survival of Patients with Myelofibrosis Treated with Ruxolitinib—A Real-Life Longitudinal Study
por: Stoeva, Vera, et al.
Publicado: (2023)

Incretins and SGLT-2i Therapy of Type 2 Diabetes – Real Life Study of Their Therapeutic and Economic Effects
por: Mitkova, Zornitsa, et al.
Publicado: (2019)

Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib
por: Stoeva, Vera, et al.
Publicado: (2023)

Review of medicine utilization for Parkinson’s disease management: The Bulgarian perspective
por: Mitkova, Zornitsa, et al.
Publicado: (2021)

Coronavirus disease 2019 (COVID-19) during pregnancy in patients with rheumatic diseases
por: Boyadzhieva, Vladimira Vasileva, et al.
Publicado: (2020)

Evaluation of potentially inappropriate medication in older patients with cardiovascular diseases—STOPP/START-based study
por: Krustev, Tzvetan, et al.
Publicado: (2022)

Analysis of Healthcare Expenditures in Bulgaria
por: Mitkova, Zornitsa, et al.
Publicado: (2022)

Budget cap and pay-back model to control spending on medicines: A case study of Bulgaria
por: Mitkova, Zornitsa, et al.
Publicado: (2022)

A Rare Case of Anca Positivity and Antiphospholipid Antibodies in a Patient with Takayasu Arteritis: Case Report and Review of the Literature
por: Dacheva, Rositsa, et al.
Publicado: (2023)

Life expectancy and survival analysis of patients with diabetes compared to the non diabetic population in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2020)

New Epidemiological, Clinical and Economic Data for Patients With Acromegaly in Bulgaria
por: Kamusheva, Maria, et al.
Publicado: (2020)

Association of single nucleotide polymorphism at position −308 of the tumor necrosis factor-alpha gene with ankylosing spondylitis and rheumatoid arthritis
por: Manolova, Irena, et al.
Publicado: (2014)

A Systematic Review of Collective Evidences Investigating the Effect of Diabetes Monitoring Systems and Their Application in Health Care
por: Kamusheva, Maria, et al.
Publicado: (2021)

Barriers to Use Artificial Intelligence Methodologies in Health Technology Assessment in Central and East European Countries
por: Tachkov, Konstantin, et al.
Publicado: (2022)

Chronic Hepatitis C-Related Cirrhosis Hospitalization Cost Analysis in Bulgaria
por: Dimitrova, Maria, et al.
Publicado: (2017)

Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries
por: Kamusheva, Maria, et al.
Publicado: (2018)

Adherence to Acromegaly Treatment and Analysis of the Related Factors—A Real-World Study in Bulgaria
por: Kamusheva, Maria, et al.
Publicado: (2023)

Humanistic and economic aspects of haemophilia treatment in Bulgaria. Comparison between two therapeutic approaches: prophylactic vs. on-demand treatment
por: Petrova, Guenka, et al.
Publicado: (2014)

Biosimilar Insulins and Their Impact on Prices and Utilization of Insulins in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2021)

Assessment of Crystals in the Synovial Fluid of Psoriatic Arthritis Patients in Relation to Disease Activity
por: Geneva-Popova, Mariela, et al.
Publicado: (2022)

Comparisons of +3179G/A insulin-like growth factor 1 receptor gene distribution between two inflammatory arthritides and healthy adults
por: IVANOVA, Mariana, et al.
Publicado: (2021)

Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting
por: de Camargo, Mayara Costa, et al.
Publicado: (2019)

Traditional Tibetan medicine: therapeutic potential in rheumatoid arthritis
por: Yu, Liqiong, et al.
Publicado: (2022)

Genetic variations in GPSM3 associated with protection from rheumatoid arthritis affect its transcript abundance
por: Gall, BJ, et al.
Publicado: (2016)

Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study
por: Nasonov, Evgeniy, et al.
Publicado: (2022)

Cost-effectiveness of janus kinase inhibitors for rheumatoid arthritis: A systematic review and meta-analysis of cost-utility studies
por: Kumar, S. Sajith, et al.
Publicado: (2022)

Assessment of the expectancy, seriousness and severity of adverse drug reactions reported for chronic obstructive pulmonary disease therapy
por: Petrova, Guenka, et al.
Publicado: (2017)

An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries
por: Kamusheva, Maria, et al.
Publicado: (2018)

Research Progress of Therapeutic Enzymes and Their Derivatives: Based on Herbal Medicinal Products in Rheumatoid Arthritis
por: Cai, Ming, et al.
Publicado: (2021)

Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis
por: Huizinga, T. W. J., et al.
Publicado: (2017)

Real-world effectiveness of biological therapy in patients with rheumatoid arthritis: Systematic review and meta-analysis
por: de Castro, Caroline Tianeze, et al.
Publicado: (2022)

Combination effects of herbal and western medicines on osteoporosis in rheumatoid arthritis: systematic review and meta-analysis
por: Kwon, Do Young, et al.
Publicado: (2023)

Modeling the Pharmacotherapy Cost and Outcomes of Primary Open-Angle Glaucoma With Dry Eye
por: Tachkov, Konstantin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8m7a16ql8o28ddh9dcad4n5j09